Target
CTLA4
33 abstracts
Abstract
Dual-agent immunotherapy for prevention of melanoma brain metastases: A real-world analysis of 8686 patients.Org: Penn State Milton S. Hershey Medical Center, Hershey, PA, Penn State College of Medicine, University Park, PA, University of Toronto,
Abstract
Triplet combination treatments with pembrolizumab (pembro) for anti–PD-(L)1–refractory advanced melanoma: Preliminary results of the phase 1/2 KEYMAKER-U02A study.Org: University Hospital Zurich, Aix-Marseille University CHU Timone, Hôpital de la Timone, Department of Cancer Medicine, Gustave Roussy Cancer Centre, Gustave Roussy Cancer Campus,
Abstract
A phase 1/2, safety lead-in and dose expansion, open-label, multicenter trial investigating the safety, tolerability, and preliminary activity of ivosidenib in combination with nivolumab and ipilimumab in previously treated subjects with IDH1-mutated nonresectable or metastatic cholangiocarcinoma.Org: Servier Pharmaceuticals LLC,
Abstract
High dose bolus (HDB) interleukin-2 (IL2) and concurrent low dose ipilimumab followed sequentially by nivolumab in patients with advanced melanoma after failure of anti-PD1-based immunotherapy and BRAF-MEK inhibition.Org: Departments of Cutaneous Oncology and Immunology,
Abstract
Phase II study of neoadjuvant durvalumab and tremelimumab in combination with gemcitabine and cisplatin in patients with intrahepatic cholangiocarcinoma that is borderline resectable or resectable with high risk for recurrence.Org: Lombardi Comprehensive Cancer Center, Georgetown University Medical Center, MedStar Health,
Abstract
A prognostic model based on selected cell state and cellular community scores in patients with advanced melanoma treated with immune checkpoint inhibitors (Ecotype-ICI score) as a predictor of ICI immunotherapeutic benefits.Org: Huntsman Cancer Institute and Department of Neurosurgery, University of Kentucky Markey Cancer Center, University of Iowa Hospitals and Clinics Holden Comprehensive Cancer Center, Division of Cancer Treatment and Diagnosis National Cancer Institute National Institutes of Health, Melanoma Program UPMC Hillman Cancer Center,
Abstract
Efficacy and safety of cadonilimab plus anti-EGFR monoclonal antibody as de-chemotherapy regimen in persistent, recurrent, or metastatic gynecologic cancer.Org: The First Affiliated Hospital of Xi'an Jiao Tong University, Xi'an, China,
Abstract
Combining the potency of a neoantigen-expressing DNA vector, an anti-CTLA-4 antibody, and an attenuated poxvirus in a personalized immunization platform: Preclinical studies of ODI-2001.Org: Odimma Therapeutics, myNEO,
Abstract
A first-in-human, phase I, dose-escalation study to evaluate pharmacokinetics, safety, and tolerability of KD6001, a novel anti-CTLA-4 monoclonal antibody (mAb) in patients with advanced solid tumors.Org: Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education/ Beijing),
Abstract
Length of treatment after partial or complete remission in immunotherapy for metastatic melanoma: An EUMelaReg real world study.Org: Beilinson Medical Center, EuMelaReg, Military Medical Academy, National Cancer Center Bulgaria, University of Kiel,
Abstract
Immune checkpoint inhibitor (ICI) rechallenge after immune-related adverse events (irAE) requiring hospitalization: A single-center 10-year experience.Org: Far Eastern Memorial Hospital, Salem,
Abstract
Clinical and immune phenotypes associated with immune checkpoint inhibitor-induced autoimmune diabetes.Org: Massachusetts General Hospital, Brigham and Women's Hospital, Newton,
Abstract
DURTRERAD: A phase II open-label study evaluating feasibility and efficacy of durvalumab (D) and durvalumab plus tremelimumab (DT) in combination with radiotherapy (RT) in non-resectable locally advanced HPV-negative head and neck squamous cell carcinoma (LA-HNSCC).Org: Charité-Universitätsmedizin Berlin, Humboldt-Universität zu Berlin, Berlin Institute of Health, University Hospital Essen, West German Cancer Center, University Hospital Essen,
Abstract
A phase II basket trial of dual anti–CTLA-4 and anti–PD-1 blockade in rare tumors (DART) SWOG S1609: The vulvar cancers.Org: Northwestern University, Feinberg School of Medicine, Robert H. Lurie Comprehensive Cancer Center, Chicago, IL, Il-Yang Pharmaceuticals, Fred Hutchinson Cancer Center/Division of Hematology and Oncology, Seattle Gummy Company,
Abstract
Transcriptional metabolic profiling in young onset colorectal cancer (CRC) patients.Org: University of Kentucky, Ohio State University Wexner Medical Center, Ohio State University James Cancer Hospital Department of Radiation Oncology, Roswell Park Comprehensive Cancer Center, Moffitt Cancer Center,
Abstract
Risk of further progression or death among durable progression-free survivors with melanoma in PD-1 blockade trials: Implications for imaging surveillance.Org: Roswell Park Comprehensive Cancer Center, Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins,
Abstract
Characterization of the immunophenotype and tumor specificity of CD8+ T-cells in chromophobe renal cell carcinoma (ChRCC) and renal oncocytic neoplasms.Org: Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA, St. Elizabeth's Medical Center, Brighton, MA,
Abstract
Clinical genomic implications of transcriptional subtypes in pancreatic cancer.Org: Dana-Farber Cancer Institute, Brookline, MA, Boston, MA, Caris Life Sciences, Irving, TX, Phoenix, AZ,
Abstract
Edema and serositis as an adverse event in patients with cancer receiving immune checkpoint blockade: Systematic review to evaluate this immune-related adverse event and associated treatment strategies.Org: Mount Sinai Beth Israel, Center for Thoracic Oncology, Tisch Cancer Institute, Icahn School of Medicine at Mount Sinai/Tisch Cancer Institute, Department of Medicine, Icahn School of Medicine at Mount Sinai,
Abstract
Machine learning (ML)-based quantification of tumor-infiltrating lymphocytes (TIL) and clinical outcomes of patients with melanoma treated with immune-checkpoint inhibitors (ICI).Org: Brigham and Women's Hospital/Massachusetts General Hospital, University Hospital of North Norway, Yale Cancer Center, Yale School of Medicine, New Haven, CT, Dana-Farber Cancer Institute,
Abstract
Identification of genes encoding targets associated with adverse events in multiple myeloma.Org: Kansas State University–Olathe, Taussig Cancer Center, Cleveland Clinic Taussig Cancer Instititute, University of Missouri Kansas City, Indiana University/Melvin and Bren Simon Cancer Center,
Abstract
A prospective observational study investigating the impact of immune checkpoint inhibitors for cancer on fertility in males and females of child-bearing age (immuno-fertility).Org: Beaumont RCSI Cancer Centre, Merrion Fertility Clinic, Beaumont Hospital Cancer Centre, The Merrion Fertility Clinic, Merrion Fertility Clinic & National Maternity Hospital,
Abstract
Anticancer–drug-induced interstitial lung disease (DIILD): With great power comes great responsibility.Org: Syneos Health, Morrisville, NC, NC Medical Research, Gurugram, Indiana University – Purdue University Indianapolis,
Abstract
A Lasso Cox score consisting of CTLA4+ regulatory T cells (Treg), monocytic myeloid derived suppressor cells (M-MDSC), and CXCR3+ CD8+ T cells: Association with adjuvant ipilimumab (ipi) survival outcomes in patients (pts) with high-risk melanoma.Org: H. Lee Moffitt Cancer Center and Research Institute, Dana-Farber Cancer Institute, Moffitt Cancer Center, National Cancer Institute/National Institutes of Health, University of Pittsburgh School of Medicine and UPMC Hillman Cancer Center,
Abstract
Exploring the potential of combination immune checkpoint strategies in non-small cell lung cancer (NSCLC).Org: Mayo Clinic, The University of Texas MD Anderson Cancer Center, Stem Cell Transplantation Rsch, Houston, TX, University of Alabama at Birmingham Department of Hematology, Birmingham, AL, University of Alabama-Birmingham,
Abstract
Nature and management of melanoma recurrences following adjuvant anti-PD-1 (PD1) therapy.Org: Melanoma Institute Australia, Netherlands Cancer Institute (NKI), Department of Dermatology, APHP St Louis, Alfred Health,
Abstract
Large versus limited molecular profiling panel screening program in patients with metastatic sarcoma: An exploratory subgroup analysis from the ProfiLER 02 trial.Org: Centre Léon-Bérard, Centre Léon Bérard, Centre Oscar Lambret, Institut Claudius Regaud/IUCT-Oncopole, Centre Eugène Marquis,
Abstract
Anti-PD1 plus BRAF/MEK inhibitors (triplet therapy) after failure of standard therapy in patients (pts) with advanced melanoma.Org: University Hospital Essen, University Hospital Zurich, Melanoma Institute Australia, University Hospital Heidelberg, Universitaetsklinikum Erlangen,
Abstract
Retreatment with nivolumab and ipilimumab with or without chemotherapy in patients with metastatic non-small cell lung cancer after progression on immune checkpoint inhibitor therapy.Org: Lausanne University Hospital, Geneva University Hospitals,
Abstract
Implications of GITR expression profile for precision immunotherapeutics.Org: Moores Cancer Center, UC San Diego Health, Medical College of Wisconsin and WIN Consortium, Dartmouth Cancer Center, Lebanon, NH, OmniSeq (Labcorp), OmniSeq Inc. (Labcorp),
Abstract
Combined immune checkpoint inhibition with durvalumab and tremelimumab with and without radiofrequency ablation in patients with advanced biliary tract carcinoma.Org: Center for Cancer Research, National Cancer Institute, Biostatistics and Data Management Section, OCD, NCI, NIH, Bethesda, MD, Radiology and Imaging Sciences, CCR, NCI, NIH, Bethesda, MD, Center for Interventional Oncology, Thoracic and GI Oncology Branch,
Abstract
Dissecting the relationship between ethnicity and response to checkpoint inhibitors in patients with acral melanoma.Org: The University of Texas MD Anderson Cancer Center, Stem Cell Transplantation Rsch, Houston, TX, University of Texas MD Anderson Cancer Center, MD Anderson Cancer Center,
Abstract
An open-label, multicenter, adaptive, phase Ib/II study of QL1706 or QL1604 plus bevacizumab as first-line treatment in patients with advanced hepatocellular carcinoma.Org: Department of Abdominal Oncology, West China Hospital of Sichuan University, Chengdu, China, Department of Gastroenterology Second Ward, Harbin Medical University Cancer Hospital, Harbin, China, Department of Intervention,Hunan Cancer Hosptial, Changsha, China, Liver Tumor Center, Nanfang Hospital Southern Medical University, Guangzhou, China, Phase I Clinical Research Room,Nanfang Hospital Southern Medical University, Guangzhou, China,